ASX Announcement
30 October 2026

Cleansing Notice

The Board of Invex Therapeutics Limited (ASX: IXC) ("Invex" or "the Company") hereby provides notice pursuant to section 708A(5)(e) of the *Corporations Act 2001* (Cth) (Corporations Act), that

The Company:

1. On 30 October 2026, the Company issued 11,250,000 Shares at an issue price of $0.08 (8 cents) per Share to sophisticated and professional investors, to raise $900,000, before costs, pursuant to the Preliminary Placement announced on ASX on 26 October 2026;
2. The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
3. The Company is providing this notice under section 708A(5)(e) of the Corporations Act;
4. As at the date of this notice the Company has complied with:
    - The provisions of Chapter 2M of the Corporations Act as they apply to Company;
    - Section 674 of the Corporations Act; and
5. As at the date of this notice, there is no information that is "excluded information" (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company.

An Appendix 2A in respect of the issue of the above securities was released 30 October 2026.

This release dated 30 October 2026 has been authorised for lodgement to the ASX by the Board of the Company

ENDS

For more information, please contact:

Company/Investors
Mr David Wheeler
Non-Executive Director
+61 8 6558 0886

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com